RESECTABLE PANCREATIC DUCTAL ADENOCARCINOMA (PDAC)

Clinical trials for RESECTABLE PANCREATIC DUCTAL ADENOCARCINOMA (PDAC) explained in plain language.

Never miss a new study

Get alerted when new RESECTABLE PANCREATIC DUCTAL ADENOCARCINOMA (PDAC) trials appear

Sign up with your email to follow new studies for RESECTABLE PANCREATIC DUCTAL ADENOCARCINOMA (PDAC), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 1 Completed 1

New hope to keep pancreatic cancer from returning after surgery

Disease control Recruiting now

This study is testing whether a new oral drug, daraxonrasib, can help keep pancreatic cancer from coming back after surgery and chemotherapy. It will compare the drug to standard observation (no drug) in 500 patients who have had their tumor surgically removed and completed chemo…

Matched conditions: RESECTABLE PANCREATIC DUCTAL ADENOCARCINOMA (PDAC)

Phase: PHASE3 • Sponsor: Revolution Medicines, Inc. • Aim: Disease control

Last updated Mar 09, 2026 14:25 UTC

RESECTABLE PANCREATIC DUCTAL ADENOCARCINOMA (PDAC)

Get alerted when new RESECTABLE PANCREATIC DUCTAL ADENOCARCINOMA (PDAC) trials appear

New hope to keep pancreatic cancer from returning after surgery